ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 preview – toxicity looms large for J&J
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
The group is keeping faith with the novel target KLK2.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
